Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care f...
Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worl...
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedente...
Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-ins...
Aignostics announced the launch of HETA Clinical, a new family of pan-cancer AI products spanning the pathology workflow from intake and evaluation to mole...
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, and Framatome...
Alentis Therapeutics and PinotBio announced they have entered into a research collaboration and licensing agreement to discover and develop next-generation...
As demand for injectable therapies grows and manufacturing requirements become more complex, Vetter Pharma is expanding its global fill-finish network to...
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete sy...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allos...
Andelyn Biosciences (“Andelyn”), a leading US-based patient-focused cell and gene therapy Contract Development and Manufacturing Organization (...
Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with...
Strategic collaboration combines Italfarmaco’s leadership in HDAC biology and therapeutic development with VeriSIM Life’s Mechanistic AI dr...
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2...
© 2026 Biopharma Boardroom. All Rights Reserved.
